NEPC tumors share some common genetic aberrations as prostate adenocarcinoma, such as TMPRSS2-ERG fusion and loss of RB1 and TP53, but often do not express AR and downstream AR-regulated targets such as PSA and prostate-specific membrane antigen (PSMA) (6). This evidence concerns the gene FOLH1 and prostate adenocarcinoma.